Home > Resources > Whitepapers > Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma

Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma

October 30, 2018

Follow-on drugs, also referred to as ‘next-generation drugs’, are ‘an established practice’ among drug innovators. They are one of the most effective R&D strategies implemented by drug innovators, and can be considered a cannibalization or switching strategy. In a nutshell, it is a timely switch from a mature/firstgeneration drug to its next-generation, improved version. Given the fixed patent term and limited market exclusivity of drugs, cannibalization has been instrumental in maintaining the market share for drug makers.

Spotlight

GeBBS Healthcare Solutions

GeBBS Healthcare Solutions is a leading technology-enabled provider of revenue cycle management (RCM) solutions. GeBBS’ innovative technology, combined with its over 6,000-strong global workforce, helps clients improve financial performance, compliance, and patient satisfaction. GeBBS solutions include Health Information Management (HIM), eligibility and verification, accounts receivable management, and patient access.

OTHER WHITEPAPERS

Overcoming The Challenges of Pediatric Formulation

whitePaper | February 15, 2023

Pediatric populations represent the most diverse patient groups in all of medicine. Factors such as individual preferences, physiology, and dosage considerations all serve to complicate drug formulation aimed at pediatric care.

Latest Evidence and Effects of Vitamin D3 (cholecalciferol)-Drug Interactions

whitePaper | October 15, 2022

Because vitamin D receptors are present in most cells in the body, its active form has potent effects on the growth and differentiation of many types of cells, meaning that vitamin D

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Advancements in Drug Development and Formulation

whitePaper | December 13, 2022

A recent e-symposium presented insights into the latest research and innovative solutions to help shorten timeto-market, reduce development costs, increase yield, and assure quality and pharmacopoeia compliance throughout the drug development process.

Deck 7 Webinars and Virtual Events

whitePaper | January 1, 2020

If you recognize some of these challenges, download the Deck 7 Webinar & Virtual Events overview to see how we make it easy for busy marketers to run highly successful webinars and virtual events....

Medical Afairs Transformation in Specialty Pharma

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.